• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dexcom, Beyond Type 2 and Retta Establish National Glucose Awareness Week to Close the Glucose Knowledge Gap

    9/23/24 9:00:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care
    Get the next $DXCM alert in real time by email
    • National Glucose Awareness Week will take place from Sept. 23-29, 2024, and will encourage people to learn about the importance of glucose and its significant impact on overall health, especially for people with diabetes.
    • Retta, actress from Parks and Recreation, Good Girls and Hit Man, who is managing Type 2 diabetes, will inspire others to get involved.
    • Visit GetGlucoseAware.com to learn more about the initiative and help spread the word.

    DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, in partnership with the nonprofit Beyond Type 2, are teaming up with author, producer and actress Retta to establish National Glucose Awareness Week from Sept. 23-29, 2024. National Glucose Awareness Week will help close the glucose knowledge gap and encourage people to take action to own their glucose health.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240923896101/en/

    Actress Retta teams up with Dexcom and Beyond Type 2 to establish National Glucose Awareness Week. (Photo: Business Wire)

    Actress Retta teams up with Dexcom and Beyond Type 2 to establish National Glucose Awareness Week. (Photo: Business Wire)

    Understanding glucose health and keeping glucose levels stable are especially critical for people living with diabetes or prediabetes, but a recent survey* found that only 10% of people with Type 2 diabetes or prediabetes said they understand the factors that cause changes in their glucose levels "extremely well."1 The same survey also found that since receiving their diagnosis, 45% of people with Type 2 diabetes not using insulin or prediabetes have faced confusion about how to effectively manage the condition, and half have faced decreased confidence in their overall health.1

    National Glucose Awareness Week will feature a variety of educational resources about the importance of glucose health and information about new, cutting-edge glucose biosensing technology. Glucose biosensors reveal how food, exercise and sleep affect glucose and provide easy-to-understand insights to help people better manage their glucose levels. The week will also include chances for participants to win prizes as they expand their knowledge and spread the word about the importance of being glucose aware.

    "Since being diagnosed with Type 2 diabetes, I've needed to learn how different lifestyle factors such as diet and exercise can impact my glucose levels and my overall health," said Retta, the actress well-known for her roles in Parks and Recreation, Good Girls, and Hit Man. "Since I started using Stelo, Dexcom's newest glucose biosensor, I've improved my glucose awareness. That is why I'm proud to partner with Dexcom and Beyond Type 2 to help others increase their glucose knowledge."

    Visit GetGlucoseAware.com today to:

    • Get aware: Watch Retta share knowledge about glucose health, then get rewarded with the chance to win prizes for sharing your newfound knowledge with others.
    • Get moving: Participate in a nationwide step challenge (invitation code: glucose) from Sept. 30 to Oct. 13 to help improve your glucose health.† Step challenge participants can register to participate from Sept. 23-29, 2024 and will have the chance to compete for prizes.
    • Get resources: Close the glucose knowledge gap with key educational resources from Beyond Type 2.

    National Glucose Awareness Week isn't just for people already diagnosed with diabetes or prediabetes. A staggering one-third of the U.S. population have diabetes or prediabetes, and alarmingly, more than 20% of those with Type 2 diabetes not using insulin and 80% of those with prediabetes are unaware of their condition.2

    "Through this initiative, we hope to provide people with valuable information that can lead to earlier detection of prediabetes and Type 2 diabetes," said Melanie Batchelor, Manager of Health Impact Content and Community Education at Beyond Type 2. "We're proud to be part of this awareness campaign and support those living with diabetes with resources designed to help them thrive."

    About DexCom, Inc.

    DexCom, Inc. empowers people to take control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, Calif., and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers and providers, Dexcom works to simplify and improve diabetes management around the world. For more information on Dexcom, visit https://www.dexcom.com/about.

    About Beyond Type 1

    Beyond Type 1 is a nonprofit organization that is changing what it means to live with diabetes. Through platforms, programs, resources, and grants, Beyond Type 1 is uniting the global diabetes community and providing solutions to improve lives today. Founded in 2015 with a focus on education, advocacy, and the pathway to cures for type 1 diabetes, in 2019 the organization launched its Beyond Type 2 programming. A new model of philanthropy, Beyond Type 1 and Beyond Type 2 aim to change what it means to live with chronic illness.

    *Dexcom-Stelo Survey of 1,850 U.S. individuals aged 18 and older, including individuals without prediabetes or type 2 diabetes, those with prediabetes or type 2 diabetes not using insulin, and healthcare providers who work with prediabetes and Type 2 patients, conducted May/June 2024. †Registration is open to U.S. residents only on a first-come, first-served basis, up to 3,000 participants, from Sept. 23-29, 2024. The Step Challenge will be run by IncentFit; for full terms and conditions, visit https://getglucoseaware.com/wp-content/uploads/2024/09/Stelo-Glucose-Step-Challenge-V-1.4-BT1.pdf.

    1 Dexcom, data on file, 2024. 2 Centers for Disease Control. National Diabetes Statistics Report. www.cdc.gov. Accessed 9/16/24. https://www.cdc.gov/diabetes/php/data-research/index.html.

    STELO IMPORTANT INFORMATION: Consult your healthcare provider before making any medication adjustments based on your sensor readings and do not take any other medical action based on your sensor readings without consulting your healthcare provider. Do not use if you have problematic hypoglycemia. Failure to use Stelo and its components according to the instructions for use provided and to properly consider all indications, contraindications, warnings, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence. If your sensor readings are not consistent with your symptoms, a blood glucose meter may be an option as needed and consult your healthcare provider. Seek medical advice and attention when appropriate, including before making any medication adjustments and/or for any medical emergency.

    INDICATIONS FOR USE: The Stelo Glucose Biosensor System is an over-the-counter (OTC) integrated Continuous Glucose Monitor (iCGM) intended to continuously measure, record, analyze, and display glucose values in people 18 years and older not on insulin. The Stelo Glucose Biosensor System helps to detect normal (euglycemic) and low or high (dysglycemic) glucose levels. The Stelo Glucose Biosensor System may also help the user better understand how lifestyle and behavior modification, including diet and exercise, impact glucose excursion. The user is not intended to take medical action based on the device output without consultation with a qualified healthcare professional.

    Dexcom, Dexcom Clarity, Dexcom Follow, Dexcom One, Dexcom Share, Stelo, and any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries. ©2024 DexCom, Inc. All rights reserved.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240923896101/en/

    Get the next $DXCM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DXCM

    DatePrice TargetRatingAnalyst
    1/12/2026$71.00Equal Weight → Underweight
    Barclays
    12/2/2025$75.00Equal-Weight → Overweight
    Morgan Stanley
    11/25/2025$68.00In-line
    Evercore ISI
    10/21/2025$85.00Buy
    Stifel
    9/8/2025Outperform → Perform
    Oppenheimer
    8/21/2025$100.00Buy
    Argus
    6/16/2025$102.00Buy
    Truist
    5/30/2025$104.00Buy
    Goldman
    More analyst ratings

    $DXCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Heller Bridgette P sold $68,826 worth of shares (1,012 units at $68.01), decreasing direct ownership by 4% to 26,019 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    2/17/26 4:36:44 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    President, CEO, and Director Leach Jacob Steven was granted 8,310 shares and covered exercise/tax liability with 3,058 shares, increasing direct ownership by 2% to 337,051 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    2/2/26 4:46:44 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    EVP, Chief HR Officer Stern Sadie was granted 7,123 shares and covered exercise/tax liability with 2,656 shares, increasing direct ownership by 4% to 109,690 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    2/2/26 4:46:39 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    SEC Filings

    View All

    SEC Form 10-K filed by DexCom Inc.

    10-K - DEXCOM INC (0001093557) (Filer)

    2/12/26 5:20:56 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    DexCom Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DEXCOM INC (0001093557) (Filer)

    2/12/26 4:03:42 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    DexCom Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DEXCOM INC (0001093557) (Filer)

    1/12/26 7:30:45 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Dexcom downgraded by Barclays with a new price target

    Barclays downgraded Dexcom from Equal Weight to Underweight and set a new price target of $71.00

    1/12/26 8:59:23 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Dexcom from Equal-Weight to Overweight and set a new price target of $75.00

    12/2/25 8:17:55 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Evercore ISI initiated coverage on Dexcom with a new price target

    Evercore ISI initiated coverage of Dexcom with a rating of In-line and set a new price target of $68.00

    11/25/25 8:40:45 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & COO Leach Jacob Steven bought $1,001,702 worth of shares (18,200 units at $55.04), increasing direct ownership by 6% to 331,697 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/10/25 7:13:08 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights: Revenue grew 13% year-over-year to $1.260 billion on a reported basis and 12% year-over-year on an organic1 basis. U.S. revenue grew 11% and international revenue grew 18% on a reported basis and 15% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $323.0 million or 25.6% of revenue, an increase of 860 basis points compared to the fourth quarter of 2024. Non-GAAP operating income* of $331.5 million or 26.3% of reported revenue, an increase of 750 basis points compared to the fourth

    2/12/26 4:03:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Stelo Adds Enhanced Smart Meal Logging Features as Dexcom Continues to Transform Personal Glucose Management

    Enhanced Smart Food Logging experience now provides nutritional breakdown of meals Advanced AI-enabled features will deliver easy meal tracking to transform daily metabolic health management Redesigned and personalized Daily Insights will reveal how daily performance and behaviors impact health Dexcom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced it will roll out an advanced AI-enabled enhancement to Stelo that will transform how users understand their glucose health and take steps in achieving their long-term health goals. The newest features will launch nationwide in the coming weeks. This press release features multimedia. View the full release here:

    2/4/26 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Schedules Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call for February 12, 2026 at 4:30 p.m. Eastern Time.

    DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2025 financial results after market close on Thursday, February 12, 2026. Management will hold a conference call to review the company's fourth quarter and fiscal year 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" appr

    1/27/26 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/13/24 5:02:33 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/9/23 11:16:37 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/9/22 3:43:37 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Leadership Updates

    Live Leadership Updates

    View All

    Dexcom Appoints Euan Ashley to Board of Directors

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025. Dr. Ashley is a renowned researcher, entrepreneur, and clinician with extensive leadership experience at healthcare research institutions and private organizations. He currently serves as Chair of the Department of Medicine at Stanford University, overseeing Stanford's largest department with 15 divisions and over 800 faculty. Dr. Ashley's research extends across precision medicine, data science, artificial intelligence, and digital health. He has also co-founded seven biotechnology companies and serves as the co-directo

    10/27/25 4:15:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Synchron Expands Executive Team with Appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D

    Medical device leaders who have built and scaled category-defining products join Synchron to help drive its next-generation brain-computer interface platform as well as accelerate towards commercialization Synchron, a category-defining brain-computer interface (BCI) company, today announced the appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D. The appointments bring deep experience in launching and scaling category-leading medical devices, positioning Synchron to advance its Stentrode® BCI through U.S. clinical trials and prepare for global market entry. Mr. Rasdal, who joined Synchron's Board of Directors in 2023, will transition into a full-time executive role

    8/19/25 8:00:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews

    Dexcom's first-of-its-kind NIL program welcomes 13 new athletes and eight returning team members, including San Diego State University basketball standout Miles Byrd and Alabama A&M University's Shelomi Sanders The trailblazing program empowers college athletes with Type 1 diabetes to break barriers in sports and inspire their communities, as showcased at the Dexcom U Signing Day Camp, a new addition to the program, earlier this month DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes. This pr

    7/17/25 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Financials

    Live finance-specific insights

    View All

    Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights: Revenue grew 13% year-over-year to $1.260 billion on a reported basis and 12% year-over-year on an organic1 basis. U.S. revenue grew 11% and international revenue grew 18% on a reported basis and 15% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $323.0 million or 25.6% of revenue, an increase of 860 basis points compared to the fourth quarter of 2024. Non-GAAP operating income* of $331.5 million or 26.3% of reported revenue, an increase of 750 basis points compared to the fourth

    2/12/26 4:03:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Schedules Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call for February 12, 2026 at 4:30 p.m. Eastern Time.

    DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2025 financial results after market close on Thursday, February 12, 2026. Management will hold a conference call to review the company's fourth quarter and fiscal year 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" appr

    1/27/26 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

    DexCom, Inc. (NASDAQ:DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2025 with total revenue of approximately $1.260 billion, an increase of 13% over the fourth quarter of 2024. U.S. revenue is expected to be approximately $892 million, representing growth of 11% over the fourth quarter of 2024. International revenue is expected to be approximately $368 million, an increase of 18% over the fourth quarter of 2024. For fiscal 2025, total preliminary, unaudited revenue is approximately $4.662 billion, an increase of 16% over 2024. In conjunction with the preliminary fourth quarter results, the company is also reiterating 2025 non-GAAP gross profi

    1/12/26 7:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care